天演药业 ADAG 深 沪
等待开盘 04-02 09:30:00 美东时间
4.61
+0.690
+17.60%
华盛通- 最 高4.72
- 今 开3.9177
- 成交量 22.29万股
- 最 低 3.9177
- 昨 收 3.92
- 总市值 2.17亿
- 52周最高 4.72
- 市盈率 静 --
- 换手率 0.47%
- 52周最低 1.30
- 委 比 -95.92%
- 总股本 4713.13万
- 历史最高 31.83
- 量 比 1.88
- 振 幅 20.47%
- 历史最低 0.90
- 每 手 1
- 风险率 0.60%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Adagene sets $3.75 per ADS price for $70M offering
Adagene (ADAG) stock slumped ~14% on Thursday during pre-market as it priced an underwritten public offering of ADS, aiming to raise approximately $70M in gross proceeds. The company is offering ~18.6...
今天 19:35
Adagene Collaborates With Incyte To Evaluate Combination Of Muzastotug And INCA33890 In Patients With Microsatellite Stable Colorectal Cancer With Or Without Liver Metastases
Phase 1 study of INCA33890 and muzastotug expected to begin in 2026 in 3L MSS CRC patients with and without liver metastasesStudy will be sponsored and conducted by Incyte; Adagene to provide clinical supply of
今天 19:04
Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs
Adagene Inc. announced the pricing of its underwritten public offering of 18,666,000 ADSs at US$3.75 per ADS, raising approximately US$70 million. The offering is expected to close on April 6, 2026, with Leerink Partners and LifeSci Capital as joint book-running managers, and Lucid Capital Markets as co-manager. Participation includes notable investors like Janus Henderson Investors and Deerfield Management. The offering details were filed with t...
今天 11:10
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)
Adagene Inc. and Incyte announced a clinical collaboration to evaluate the combination of muzastotug (ADG126) and INCA33890 in patients with microsatellite stable colorectal cancer (MSS CRC) with or without liver metastases. The Phase 1 study, sponsored by Incyte, aims to explore the safety, tolerability, and efficacy of the combination in 3rd-line MSS CRC patients. Muzastotug, a masked anti-CTLA-4 SAFEbody, has shown promising results in earlier...
今天 11:01
Adagene FY Adj. EPS $(0.24) Misses $(0.15) Estimate, Sales $7.671M Beat $1.667M Estimate
Adagene (NASDAQ:ADAG) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.15) by 60 percent. This is a 52.94 percent increase over losses of $(0.51) per share from the same
今天 05:07
Adagene’s Muzastotug (ADG126) to be Highlighted in Two Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA
Adagene Inc. announced that muzastotug (ADG126) will be highlighted in two poster presentations at the AACR 2026 Meeting. The first presentation evaluates muzastotug in combination with pembrolizumab and fruquintinib for advanced colorectal cancer, while the second focuses on its combination arm in hepatocellular carcinoma. Adagene specializes in antibody-based cancer therapies, utilizing its proprietary SAFEbody technology to enhance safety and ...
03-17 20:35
Palvella Therapeutics launches $150M public stock offering
Palvella Therapeutics (PVLA) announced the commencement of an underwritten public offering of $150M of its common stock. The company expects to grant underwriters a 30-day option to purchase up to an ...
02-25 05:21
Palvella surges on late-stage trial win for lead asset
Shares of Palvella Therapeutics (PVLA) rose more than 30% on Tuesday after the company announced that a late-stage trial for its lead asset, Qtorin rapamycin, reached its main goals, paving the way fo...
02-25 00:27
天演药业公布2026年临床数据公布与研发进展计划
经济观察网 天演药业公布了2026年的业务进展及年度目标，包括多项临床数据公布与研发计划。 近期事件 2026年第一季度：计划公布muzastotug（ADG...
02-18 00:47
Adagene to Participate in Two Upcoming Investor Conferences
Adagene Inc. announces that its Chief Strategy Officer, Mickael Chane-Du, will participate in investor meetings and fireside chats at the Oppenheimer 36th Annual Healthcare Life Sciences Conference (virtual on Feb. 25, 2026) and the Leerink Global Healthcare Conference (Miami, Mar. 8-11, 2026). Webcasts will be available on the Company’s website. Adagene focuses on advancing antibody-based cancer immunotherapies using innovative platforms like SA...
02-17 14:27
